

# The ISI eSolutions Conference 2009

September 29-30th Barcelona

## Press Contacts:

Lisa Meyer  
Director, Global Marketing  
973-560-0808 x. 217  
lisa.meyer@imagesolutions.com

Carina Birt  
Sarum  
+44 1722 411150  
carina@sarumconsultancy.co.uk

## ISI Unveils Prestigious Speaker Line-Up for eSolutions Conference in Barcelona

- *Keynote address by Dr. Carlos Buesa, CEO, Oryzon Genomics, Vice President of the Spanish Association of Bioenterprises, [ASEBIO](#), and President of the Association of Catalan Biotechnology Companies, [CataloniaBIO](#)*
- *Candid sessions by executives from Cellerox, GlaxoSmithKline, Sanofi-Aventis & AstraZeneca offer an unprecedented opportunity for life science leaders to address some of today's most challenging regulatory issues*

**Eschborn, Germany – AUGUST, 2009** – Image Solutions Inc. ([ISI](#)), a leading provider of electronic submissions management and publishing solutions for the life sciences industry, has unveiled a prestigious line-up of speakers for its annual eSolutions Conference in Barcelona, Spain, this September to support an agenda aimed at reinventing the regulatory function.

The ISI eSolutions Conference, now in its seventh year, takes place on 29-30 September, at the Spanish city's Hotel Arts, following the theme, "Accelerating Change in the New R&D Paradigm".

The annual event is one of the most recognised dates in the calendar for senior-level pharmaceutical executives looking to share ideas with peers, build partnerships with industry thought leaders, and hear from key experts on how they are addressing some of their most pressing challenges.

Those attending in Barcelona this September can look forward to an informative programme, with a keynote address from Dr. Carlos Buesa, Chief Executive Officer of Oryzon Genomics, one of the fastest-growing biotech companies in Spain. Dr. Buesa also serves as vice president of the Spanish biotechnology association, ASEBIO, president of the Association of Catalan Biotechnology Companies (CataloniaBio), and he is a member of the governing body of the Executive Committee of BioRegió de Catalunya, a new regional development model aimed at improving the biotechnology cluster in Catalonia. Dr. Buesa also sits on the boards of other leading biotech companies.

Dr. Buesa got his PhD in Biochemistry from the University of Barcelona, Spain. He has produced more than thirty papers and patents. He developed most of his scientific career in the Pharmacy Faculty at the University of Barcelona. After his PhD, he was awarded an EU post-doctoral fellowship with the Faculty of Medicine at the University of Ghent in Belgium where later he became Senior Investigator with the Flemish Institute of Biotechnology (VIB).

The programme will also provide a forum for a series of candid insights from the coalface, with case studies and presentations from high-profile executives, including:

- David Licht, Senior Director of Global Regulatory & Safety Operations, Allergan
- Meredith Purcell, Associate Director, Global Regulatory Publishing, Allergan
- Ulf Klingnäs, Submission Manager, AstraZeneca
- Craig Funt, Executive Director, Acquisition, Collaboration and Information Services, Bristol-Myers Squibb
- María Pascual, Director of Regulatory Affairs, Cellerix
- Todd Gerig, Technology Integrator, Eli Lilly
- Vicki Phelan, Pharmaceutical Managing Director, [EquaTerra](#)
- Stephen Hasler, VP, Regulatory Operations, GlaxoSmithKline
- Bill Snyder, Director, Information and Records Management, Pfizer
- Dr. Geoffrey Williams, e-Regulatory Liaison, Roche
- Graham Shelvey, Senior Director Worldwide Regulatory Operations, Sanofi-Aventis
- Joel Alvarez, Associate Director, Global Regulatory Operations, Shire HGT Inc.
- Tracy Baldwin, EU Regulatory Operations, Takeda
- Janis Gyzen, Assistant Director Submission Programs, Takeda
- Rick Lilley, VP, Global Regulatory Affairs at UCB Pharma

### **Why Attend?**

2009 is set to redefine the structure and dynamics of the pharmaceutical industry in a way not seen since the beginning of this decade. With increased competition, reduced resources, and financial constraints, many life science companies are seeking to reengineer current research and development practices in order to support increased regulatory requirements and complexity; expanded co-development collaboration; and a rapidly changing product development model.

The 2009 programme will incorporate more intimate panel and think-tank style discussions, interactive exchanges with Q&A sessions, alongside the main keynote speeches.

The [conference agenda](#) will cover the following topics:

- Outsourcing to improve productivity and gain competitive advantage;
- Regulatory information management;
- Consolidating pipelines and submission strategies in an age of mergers, acquisitions, and other types of collaborative partnerships;
- The status and implications of electronic submissions in emerging and expanding markets, such as the BRIC nations.

“We are thrilled by the calibre and range of industry speakers which make up our 2009 conference programme,” said ISI’s European MD Adam Sherlock. “Delegates can expect one of the most stimulating programmes to date, not to mention some fantastic opportunities to meet and share ideas with their peers.”

**Event details:**

ISI’s 7th Annual eSolutions Conference: Accelerating Change in the New R&D Paradigm

**Dates:**

Pre-conference Regulatory Update Working Session on eCTD: Mon 28 September 12:00–16:00  
Tuesday, 29 September – Wednesday, 30 September, 2009

**Venue:**

Hotel Arts Barcelona  
Marina 19-21  
Barcelona 8005 Spain  
Phone: 34 93 221 10 00  
Fax: 34 93 221 10 70

**Registration:**

To register for the conference and/or make a hotel reservation please visit

<http://www.imagesolutions.com/eSolutionsBarcelona>

**About ISI**

Founded in 1992, Image Solutions, Inc (ISI) is a proven market leader in providing submissions solutions, process services and consulting to Life Sciences companies as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firms to deliver electronic submissions to the industry and since has delivered thousands of electronic and eCTD submissions. ISI serves the top 50 pharmaceutical and biotech organisations as well as the top companies in other regulated industries.

ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the U.S., Europe and Asia. ISI also remains committed to giving back to society and sharing its success with others by donating 10 percent of annual net profits to over 20 recognised charitable organisations. For more information, visit the company website at [www.imagesolutions.com](http://www.imagesolutions.com).

**Tags:**

eCTD; NeeS; regulatory information management; electronic submissions; drug development; pharmaceutical industry; life sciences; regulatory conference; biotechnology; research and development; outsourcing.

###